Navigation Links
Wayne State University to study novel treatment for antibiotic-resistant bacteria
Date:11/16/2011

DETROIT The bacteria Enterococcus can cause infections that typically target the digestive tract or bowel; if the bacteria spread, an abdominal abscess or urinary infection could result. Enterococcus also can invade the bloodstream, leading to meningitis, pneumonia or endocarditis an infection of the heart valve. Typically the only people who become ill from this bacteria are the elderly and those who already have health issues, such as diabetes or chronic kidney failure. Enterococcus infections can be serious in these populations.

The bacteria are resistant to a number of antibiotics, but in the past, physicians were able to effectively treat Enterococcus infections with the drug vancomycin. However, during recent years, Enterococcus has become resistant to vancomycin treatment, and the new strain, known as vancomycin-resistant Enterococcus (VRE), is resistant to other antibiotics as well. It also is able to transfer its treatment-resistance abilities to unrelated bacteria such as MRSA or methicillin-resistant Staphylococcus aureus.

Researchers at Wayne State University recently received funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to study a novel antibiotic that may treat VRE infection and decrease mortality. This nearly $430,000 grant led by Michael J. Rybak, Pharm.D., M.P.H., professor of pharmacy practice and director of the Anti-Infective Research Laboratory in WSU's Eugene Applebaum College of Pharmacy and Health Sciences, will provide a better understanding and treatment of this infectious disease.

According to Rybak, daptomycin, a novel lipopeptide antibiotic, shows great promise as a new therapy for VRE infections. "This research study aims to define the dose exposure breakpoint required for daptomycin to ultimately optimize patient response to treatment and prevent the emergence of resistance," he said.

Once Rybak and his team determine the optimal doses of daptomycin, the result will be greater bactericidal activity, prevention of resistance and preservation of daptomycin as a viable antibiotic for continued clinical use.


'/>"/>

Contact: Julie O'Connor
julie.oconnor@gmail.com
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related medicine news :

1. Wayne State therapeutic marijuana use study could impact state policies, guide treatment
2. Wayne State creating computer-based drug intervention for at-risk post-partum women
3. Wayne State to develop a computer-delivered intervention for alcohol use during pregnancy
4. Wayne State University study of heroin users to examine links between stress, drug use
5. Wayne State University to study effects of risky family environments on childhood asthma
6. Wayne State researcher developing treatments for Parkinsons with aid of $2.15 million NIH grant
7. Wayne State University study aims to improve diabetes management in high-risk youth
8. Wayne State University partners with Toyota on safety research
9. Wayne State University researcher to study spinal muscular atrophy
10. Wayne State University awarded $3 million from NIH to foster science and research careers
11. Wayne State researcher receives NSF award to develop neural implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: